NeOnc Technologies Holdings, Inc. is trading at $4.69 (9.5% down) in pre-market, pulling back after a sharp prior-session rally. - This follows the company securing Investigational New Drug (IND) authorization from Abu Dhabi on June 16, 2026, for NEO212, its oral brain tumor treatment, enabling Phase 2 evaluation. - The positive regulatory news drove a 14.86% surge in the prior session, with today's move suggesting profit-taking and extended-hours liquidity dynamics.